Logo Logo

Publications by Nuciforo, P.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 4.

Journal article

Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J.; Pusztai, L. (2017): Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. In: Annals of Oncology, Vol. 28, No. 1: pp. 128-135

Prat, A.; Ortega, V.; Paré, L.; Galván, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; González, R.; Manso, L.; Martínez, J.; Llombart, A.; Peña, L. de la; di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J.; Cortés, J. (2016): Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study. In: Cancer Research, Vol. 76

Pusztai, L.; Shi, W.; Jiang, T.; Nuciforo, P.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Rimm, D.; Hatzis, C.; Pena, L. de la; Armour, A.; Piccart-Gebhart, M.; Baselga, J. (2016): Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies. In: Cancer Research, Vol. 76

Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J.; Harbeck, N. (2016): Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer. In: Oncology Research and Treatment, Vol. 39: pp. 182-183

This list was generated on Sun Apr 18 09:45:41 2021 CEST.